Holding(s) in Company

Haleon PLC
16 May 2023
 

Icon Description automatically generated

16 May 2023

 

HALEON PLC 

("Haleon" or "the Company")  

 

TR-1: Standard form for notification of major holdings  

 

1. Issuer Details

ISIN

GB00BMX86B70

Issuer Name

Haleon plc

UK or Non-UK Issuer

UK

2. Reason for Notification

An acquisition or disposal of voting rights

3. Details of person subject to the notification obligation

Name

GSK plc

City of registered office (if applicable)

BRENTFORD

Country of registered office (if applicable)

United Kingdom

4. Details of the shareholder

Name

City of registered office

Country of registered office

Vidacos Nominees Limited

London

England

5. Date on which the threshold was crossed or reached

12-May-2023

6. Date on which Issuer notified

15-May-2023

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8.A)

% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights held in issuer

Resulting situation on the date on which threshold was crossed or reached

10.350000

0.000000

10.350000

955320110

Position of previous notification (if applicable)

12.940000

0.000000

12.940000


8. Notified details of the resulting situation on the date on which the threshold was crossed or reached

8A. Voting rights attached to shares

Class/Type of shares ISIN code(if possible)

Number of direct voting rights (DTR5.1)

Number of indirect voting rights (DTR5.2.1)

% of direct voting rights (DTR5.1)

% of indirect voting rights (DTR5.2.1)

GB00BMX86B70

0

955320110

0.000000

10.350000

Sub Total 8.A

955320110

10.350000%

8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))

Type of financial instrument

Expiration date

Exercise/conversion period

Number of voting rights that may be acquired if the instrument is exercised/converted

% of voting rights

 





Sub Total 8.B1




8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))

Type of financial instrument

Expiration date

Exercise/conversion period

Physical or cash settlement

Number of voting rights

% of voting rights

 






Sub Total 8.B2




9. Information in relation to the person subject to the notification obligation

2. Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entities (please add additional rows as necessary)

Ultimate controlling person

Name of controlled undertaking

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

GSK plc (Chain 1)


2.850000


2.850000%

GSK plc (Chain 1)

GlaxoSmithKline Holdings Limited (Chain 1)

2.850000


2.850000%

GSK plc (Chain 1)

GlaxoSmithKline Finance plc (Chain 1)

2.850000


2.850000%

GSK plc (Chain 1)

Glaxo Group Limited (Chain 1)

2.850000


2.850000%

GSK plc (Chain 2)


4.740000


4.740000%

GSK plc (Chain 2)

GSK LP Limited (Chain 2)

4.740000


4.740000%

GSK plc (Chain 2)

GSK GP 1 Limited (Chain 2)

4.740000


4.740000%

GSK plc (Chain 2)

GSK (No. 1) Scottish Limited Partnership (Chain 2)

4.740000


4.740000%

GSK plc (Chain 3)


1.780000


1.780000%

GSK plc (Chain 3)

GSK LP Limited (Chain 3)

1.780000


1.780000%

GSK plc (Chain 3)

GSK GP 1 Limited (Chain 3)

1.780000


1.780000%

GSK plc (Chain 3)

GSK (No. 2) Scottish Limited Partnership (Chain 3)

1.780000


1.780000%

GSK plc (Chain 4)


0.980000


0.980000%

GSK plc (Chain 4)

GSK LP Limited (Chain 4)

0.980000


0.980000%

GSK plc (Chain 4)

GSK GP 2 Limited (Chain 4)

0.980000


0.980000%

GSK plc (Chain 4)

GSK (No.3) Scottish Limited Partnership (Chain 4)

0.980000


0.980000%

10. In case of proxy voting

Name of the proxy holder

 

The number and % of voting rights held

 

The date until which the voting rights will be held

 

11. Additional Information

This notification relates to the sale by Glaxo Group Limited (a wholly-owned subsidiary of GSK plc and the holder of other external minority interests of the GSK group) of a portion of its interest in Haleon plc. A separate notification has also been submitted today by GSK plc on behalf of Glaxo Group Limited and Glaxo Group Limited's parent undertakings (other than GSK plc) in respect of their notification obligations.

Glaxo Group Limited, GSK (No.1) Scottish Limited Partnership, GSK (No.2) Scottish Limited Partnership and GSK (No.3) Scottish Limited Partnership hold their shares in Haleon plc via a custodian, Vidacos Nominees Limited, which holds the legal title to those shares on their behalf pursuant to a custody arrangement.

12. Date of Completion

15-May-2023

13. Place Of Completion

London, England

 

Amanda Mellor, Company Secretary

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 

Companies

Haleon (HLN)
UK 100

Latest directors dealings